Christensen Sandra, Robinson Katie, Thomas Sara, Williams Dominique R
Integrative Medical Weight Management, 2611 NE 125th St, Suite 100B, Seattle, WA, USA.
Abbott Laboratories, 2900 Easton Square Place, ES1, Columbus, OH, USA.
Obes Pillars. 2024 Jul 25;11:100121. doi: 10.1016/j.obpill.2024.100121. eCollection 2024 Sep.
Obesity and type 2 diabetes mellitus (T2DM) are increasingly common in the United States and worldwide. Because both conditions are associated with serious health consequences, weight reduction is recommended by professional medical and nutrition societies to improve outcomes. Due to the striking efficacy of glucagon-like peptide receptor agonists (GLP-1RAs) and dual mechanism glucose-dependent insulinotropic polypeptide/glucagon-like peptide receptor agonists (GIP/GLP-1RAs) for weight reduction and glycemic control, there is increased utilization for patients with obesity and/or T2DM. Yet, the impact of these medications on dietary intake is less understood.
This narrative literature review summarizes clinical studies quantifying and characterizing dietary intake in people with obesity and/or T2DM using GLP-1 or GIP/GLP-1 RAs.
Though data from these studies reveal that total caloric intake was reduced by 16-39 %, few studies evaluated the actual composition of the diet.
Further research is needed to understand the unique nutritional needs of adults on GLP-1 or dual GIP/GLP-1RAs and to support the development of nutritional guidelines for these individuals.
肥胖症和2型糖尿病（T2DM）在美国及全球范围内日益普遍。由于这两种病症均会引发严重的健康后果，专业医学和营养学会建议减轻体重以改善预后。鉴于胰高血糖素样肽受体激动剂（GLP-1RAs）以及双重作用机制的葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽受体激动剂（GIP/GLP-1RAs）在减轻体重和控制血糖方面具有显著疗效，肥胖症和/或T2DM患者对其的使用有所增加。然而，这些药物对饮食摄入的影响尚不清楚。
本叙述性文献综述总结了使用GLP-1或GIP/GLP-1RAs对肥胖症和/或T2DM患者的饮食摄入进行量化和特征描述的临床研究。
尽管这些研究的数据显示总热量摄入减少了16%至39%，但很少有研究评估饮食的实际构成。
需要进一步开展研究，以了解使用GLP-1或双重GIP/GLP-1RAs的成年人的独特营养需求，并支持制定针对这些个体的营养指南。
